Adding elotuzumab to myeloma treatment decreases risk of disease progression
the ONA take:
The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced risk of disease progression or death by 30% in patients with relapsed or refractory multiple myeloma, according to a new study published online in the New England Journal of Medicine and presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, this week.
For the phase III ELOQUENT-2 trial, researchers randomly assigned 646 patients with relapsed or refractory multiple myeloma to receive lenalidomide plus dexamethasone with or without elotuzumab.
Results showed that after a median follow-up of 24.5 months, the 1-year progression-free survival rate was 68% in the elotuzumab group versus 57% in the control group. The 2-year progression-free survival rates were 41% and 27%, respectively. Researchers found that median progression-free survival was 19.4 months in the elotuzumab group compared with 14.9 months in the control group.
In regard to safety, the most common grade 3 or 4 adverse events in both groups were fatigue, lymphocytopenia, neutropenia, and pneumonia. In the elotuzumab group, 10% of patients experienced infusion-related reactions, of which the majority were grade 1 or 2.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|